iodine i 131 omburtamab

Drug Overview

iodine i 131 omburtamab is a highly specialized medical tool explored in advanced cancer care. It was designed to help patients with cancers that are very difficult to treat, especially when the cancer has spread to the brain or spinal fluid.

• Generic Name: Iodine (131I) omburtamab (often shortened to 131I-omburtamab).
• US Brand Names: Omblastys. (Note: The development of this brand name was stopped after the drug did not receive official approval.
• Drug Class: Radioimmunoconjugate / Targeted Radiotherapy / Monoclonal Antibody.
• Route of Administration: Intracerebroventricular (injected directly into the fluid-filled spaces of the brain using a medical port called an Ommaya reservoir) or Intraperitoneal (injected directly into the belly cavity).
• FDA Approval Status: Investigational / Development Terminated. This drug is not FDA-approved for general public use. In late 2022 and 2023, both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) declined to approve the medication. Following this, the company manufacturing the drug stopped its clinical development.

What Is It and How Does It Work? (Mechanism of Action)

To understand how iodine I 131 omburtamab works, it is best to think of it as a Smart Drug and a highly advanced form of Targeted Therapy. It is created by combining two different parts: a cellular “tracker” and a radioactive “weapon.”

Here is how it works at the molecular level:

1. The Tracker (The Monoclonal Antibody): The first part of the drug is “omburtamab.” This is a laboratory-made protein called a monoclonal antibody. Its main job is to patrol the body and look for a specific protein marker called B7-H3 (also known as CD276).
2. The Target (B7-H3): Normally, the human immune system acts like a police force, finding and destroying sick cells. However, cancer cells are tricky. Many aggressive solid tumors—like neuroblastoma, medulloblastoma, and certain sarcomas—produce high amounts of the B7-H3 protein on their outer surface. This protein acts like a shield, helping the tumor hide from the immune system. Healthy, normal cells have very little or none of this protein.
3. The Weapon (Iodine-131): Attached to the omburtamab tracker is a safe, controlled amount of a radioactive element called Iodine-131.
4. The Attack: When the drug is injected into the brain fluid or belly, the omburtamab antibody acts like a homing missile. It hunts down the B7-H3 receptors on the outside of the cancer cells and locks onto them. Once tightly attached, the Iodine-131 releases high-energy beta radiation directly into the cancer cell. This radiation breaks apart the DNA inside the tumor cell. When the DNA is shattered, the cancer cell cannot grow, divide, or survive. Because it specifically targets the B7-H3 protein, the drug attacks the tumor directly while sparing the healthy tissue around it.

FDA-Approved Clinical Indications

Because iodine I-131 omburtamab is an investigational agent that did not pass the final regulatory steps, it does not have official FDA-approved uses. During its active years of research, it was studied in clinical trials for the following areas:

• Oncological Uses (Investigational Only):
  • Neuroblastoma that has spread to the central nervous system (brain and spinal fluid).
  • Recurrent medulloblastoma and ependymoma.
  • Desmoplastic small round cell tumors (DSRCT) in the abdomen.
  • Diffuse intrinsic pontine glioma (DIPG).
• Non-oncological Uses:
  • None. This drug was strictly researched for severe cancers.

Dosage and Administration Protocols

Because the drug was only used in controlled clinical trials, the dosages were carefully calculated by specialized nuclear medicine doctors for each specific patient.

Dose Adjustments: Standard adjustments for mild kidney or liver problems are not formally established. This is because the drug is placed directly into a specific body cavity rather than traveling through the whole bloodstream. However, patients with severe liver or kidney failure were excluded from clinical trials to ensure their safety.

Clinical Efficacy and Research Results

Between 2020 and 2025, doctors published data showing how this drug performed in patients with extremely difficult-to-treat cancers.

For example, a major 2023 clinical study published in the Journal of Neuro-Oncology looked at 27 patients dealing with returning brain tumors (recurrent medulloblastoma and ependymoma). The study showed:

• Overall Survival: The median overall survival rate was about 1.9 years (roughly 23 months) after starting the radioactive treatment.
• Disease Progression: The progression-free survival (the amount of time the patient lived before the cancer started growing again) was about 0.4 years (around 5 months).
• Best Outcomes: The drug worked best when used as a “clean-up” tool. Patients who had no visible tumors left on their MRI scans before getting the drug did much better. For these patients, the progression-free survival jumped to 1.7 years.

Despite these scientific numbers, the drug faced major roadblocks. The FDA and EMA noted that the clinical trials only had a small number of patients and lacked proper comparison groups (control groups). Because the drug developers could not clearly prove that the medication was safer and more effective than existing treatments, the health agencies rejected it.

Safety Profile and Side Effects

Like all powerful cancer treatments, iodine I-131 omburtamab carries risks. Because it involves radiation, patients were watched very closely.

Common Side Effects (>10%)

• Headaches.
• Nausea and vomiting.
• Fever and general fatigue.
• Lowered white blood cell counts (which increases the chance of catching an infection).
• Abnormal blood test results.

Serious Adverse Events

• Increased pressure inside the brain can cause severe headaches, dizziness, or vision changes.
• Aseptic meningitis (severe inflammation of the lining of the brain and spinal cord).
• Severe myelosuppression (a dangerous drop in all blood cell counts if the radiation accidentally leaks into the main bloodstream).

Black Box Warning: Because this is an experimental drug that was never officially approved for the market, there is no FDA Black Box Warning. However, strict international radiation safety rules always applied during its use.

Management Strategies

• If severe nausea occurs, doctors provide strong anti-nausea medicines before and after the treatment.
• Headaches and brain swelling are quickly treated with steroid medicines, such as dexamethasone, to bring down the inflammation.
• If blood counts drop too low, patients might receive blood transfusions or special growth factor medicines to help their bodies make new white blood cells.

Research Areas

While the commercial development of iodine I-131 omburtamab has ended, it taught scientists a tremendous amount about Immunotherapy and targeting the B7-H3 protein. In many of the clinical trials, children with high-risk neuroblastoma received this radioactive drug shortly after undergoing an autologous stem cell transplant. The stem cell transplant helped rebuild their healthy bone marrow, while the radioactive drug was used to hunt down the microscopic cancer cells hiding in the brain fluid. Today, the medical community is using the valuable lessons learned from this drug to build newer, safer therapies—like CAR-T cells and newer antibody-drug conjugates—that target the exact same B7-H3 cancer shield.

Patient Management and Practical Recommendations

In the clinical trials where this drug was used, strict rules were put in place to protect the patient and their family.

Pre-treatment Tests to be Performed

• Thyroid Protection: Patients must take a special liquid medicine called SSKI (potassium iodide) starting a few days before the treatment. This blocks the healthy thyroid gland from absorbing stray radiation.
• Fluid Flow Test: A special scan is done to make sure the fluid in the brain and spine is flowing normally, ensuring the drug spreads evenly.
• Baseline Scans: Standard MRI or CT scans to map out the tumor.
• Pregnancy Test: A blood test is strictly required for women of childbearing age, as radiation is highly dangerous to an unborn baby.

Precautions During Treatment

• Patients will give off a small amount of radiation for a short time after the injection.
• Hospital staff use heavy lead shields and limit the amount of time they stand close to the patient’s bed.

“Do’s and Don’ts” List

• DO take the thyroid-protecting medicine (SSKI) exactly as the medical team instructs.
• DO drink plenty of water and empty your bladder often to help flush any extra radiation out of your body.
• DO tell your nurse immediately if you develop a severe headache, neck stiffness, or start vomiting.
• DON’T have close physical contact with pregnant women, babies, or young children for the number of days specified by the radiation safety officer.
• DON’T skip any follow-up blood tests, as doctors must watch your blood counts very closely.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Iodine I 131 omburtamab is an investigational agent and is not approved by the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for general clinical use. Its commercial clinical development has been discontinued. Always consult with a qualified healthcare professional or your treating oncologist regarding diagnosis, treatment options, and the most current standard of care for your specific condition.